Skip to main content

Table 3 Adverse events during 12-week period of the study

From: Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial

Adverse reactions AS group (N = 68)
Kunxian, n = 35 Placebo, n = 33
Elevated AST/ALT 3 2
Dysmenorrhea 1 0
Gastrointestinal discomfort 4 1
Leukopenia/thrombocytopenia 0 0
Urinary tract infection (urinary frequency, hematuria) 0 0
Dry throat 0 0
Drug allergy 0 0
Total 8a 3
  1. aCompared with placebo group. p > 0.05